{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE326nnn/GSE326327/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by array"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE326327"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"NanoString nCounter Mouse PanCancer Immune Profiling of CT26 tumors following chronic in vitro PMS2 inhibition and in vivo anti-PD-1 treatment","description":"NanoString nCounter immune profiling revealed that PMS2 inhibitor NP1867-pretreated tumours mounted an enhanced immune response to anti-PD-1 therapy, characterized by increased infiltration of lymphocytes, including T cells and cytotoxic populations, together with enrichment of multiple immune-related pathways. These included adaptive immune responses, antigen processing and presentation, MHC signaling, and interferon pathways, indicating that NP1867 pretreatment primes tumors for improved immunological responsiveness to PD-1 blockade.","dates":{"publication":"2026/04/21"},"accession":"GSE326327","cross_references":{"GSM":["GSM9629376","GSM9629387","GSM9629375","GSM9629386","GSM9629378","GSM9629389","GSM9629367","GSM9629388","GSM9629377","GSM9629372","GSM9629383","GSM9629382","GSM9629371","GSM9629385","GSM9629374","GSM9629373","GSM9629384","GSM9629390","GSM9629381","GSM9629370","GSM9629380","GSM9629369","GSM9629379","GSM9629368"],"GPL":["25652"],"GSE":["326327"],"taxon":["Mus musculus"]}}